Cisplatin nephrotoxicity: experimental and clinical studies
- PMID: 2178884
Cisplatin nephrotoxicity: experimental and clinical studies
Abstract
Cisplatin is currently one of the most used agents in the treatment of cancer and it is essential in the treatment of germ cell cancer. The use of the drug is hampered by side effects - especially renal toxicity which is dose limiting. The present work was undertaken to elucidate the pathophysiological mechanisms involved in cisplatin induced nephrotoxicity. Immediately after administration of cisplatin to dogs, renal blood flow (RBF) and glomerular filtration rate (GFR) remained unchanged, while proximal reabsorption rates decreased significantly. The cisplatin induced nephrotoxicity is thus initiated by an acute, mainly proximal tubular impairment, preceding alterations in renal hemodynamics. These data were confirmed in a micropuncture study in rats. At 48 to 72 hours after administration of cisplatin depressed renal function could be attributed to impairment of proximal as well as distal tubular reabsorptive capacities, now associated with increased renal vascular resistance. After administration of 4 cycles of 20 mg cisplatin/m2 d. for 5 days in humans, a small but significant decrease in 51Cr-EDTA clearance was observed. In the high-dose cisplatin group (40 mg/m2 d. for 5 days) a severe progressive decrease in GFR was observed during treatment and GFR remained decreased for up to 2 years after termination of treatment. The observation of an acute increase in N-acetyl-beta-D-glucosaminidase and beta-2-microglobulin indicates a primary tubular effect of cisplatin also in humans. A marked reduction of proximal tubular reabsorptive capacities of sodium and water was also observed in this group, together with a decrease in distal tubular function. These changes persist for at least 6 months after treatment. In the high-dose group proteinuria developed. This was mainly of tubular origin during cisplatin infusion and of glomerular origin between treatment cycles. Cisplatin remains one of the most potent antineoplastic agents ever developed. Further work should be performed to reduce its potential for renal toxicity.
Similar articles
-
Comparative study of the acute nephrotoxicity from standard dose cisplatin +/- ifosfamide and high-dose chemotherapy with carboplatin and ifosfamide.Anticancer Res. 2000 Sep-Oct;20(5C):3767-73. Anticancer Res. 2000. PMID: 11268452 Clinical Trial.
-
Cisplatin nephrotoxicity and protection by silibinin.Nephrol Dial Transplant. 1996 Jan;11(1):55-62. Nephrol Dial Transplant. 1996. PMID: 8649653
-
Mechanism of cisplatin nephrotoxicity.Fed Proc. 1983 Oct;42(13):2974-8. Fed Proc. 1983. PMID: 6684595
-
An integrative view of the pathophysiological events leading to cisplatin nephrotoxicity.Crit Rev Toxicol. 2011 Nov;41(10):803-21. doi: 10.3109/10408444.2011.602662. Epub 2011 Aug 12. Crit Rev Toxicol. 2011. PMID: 21838551 Review.
-
1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.Dan Med Bull. 2008 Nov;55(4):186-210. Dan Med Bull. 2008. PMID: 19232159 Review.
Cited by
-
Why do they die? Comparison of selected aspects of organ injury and dysfunction in mice surviving and dying in acute abdominal sepsis.Intensive Care Med Exp. 2015 Dec;3(1):48. doi: 10.1186/s40635-015-0048-z. Epub 2015 Apr 7. Intensive Care Med Exp. 2015. PMID: 26215812 Free PMC article.
-
Membrane transporters as mediators of Cisplatin effects and side effects.Scientifica (Cairo). 2012;2012:473829. doi: 10.6064/2012/473829. Epub 2012 Nov 25. Scientifica (Cairo). 2012. PMID: 24278698 Free PMC article. Review.
-
Fishing for protective compounds.Elife. 2020 Sep 3;9:e61547. doi: 10.7554/eLife.61547. Elife. 2020. PMID: 32880576 Free PMC article.
-
Nephrotoxicity of acyclovir and cis-diamminedichloroplatinum(II)--effect of co-administration in rats.J Cancer Res Clin Oncol. 1992;118(3):181-6. doi: 10.1007/BF01410131. J Cancer Res Clin Oncol. 1992. PMID: 1548282
-
A Novel Synthetic Compound, Bismuth Zinc Citrate, Could Potentially Reduce Cisplatin-Induced Toxicity Without Compromising the Anticancer Effect Through Enhanced Expression of Antioxidant Protein.Transl Oncol. 2019 May;12(5):788-799. doi: 10.1016/j.tranon.2019.02.003. Epub 2019 Mar 26. Transl Oncol. 2019. PMID: 30921749 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical
Research Materials